Danaher Corporation
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Danaher Corporation (DHR). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | Q1 2025 | Q2 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
| Diagnostics | $2.45B 42.7% | $2.31B 38.9% | $2.42B 40.6% | $2.47B 39.4% |
| Biotechnology | $1.61B 28.1% | $1.85B 31.2% | $1.80B 30.2% | $1.92B 30.6% |
| Life Sciences | $1.68B 29.3% | $1.78B 29.9% | $1.74B 29.2% | $1.88B 30.0% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
| Segment | Q1 2025 | Q2 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
| Diagnostics | $718.0M 29.3% | $554.0M 24.0% | $674.0M 27.9% | $416.0M 16.9% |
| Biotechnology | $441.0M 27.4% | $531.0M 28.7% | $534.0M 29.7% | $556.0M 29.0% |
| Life Sciences | $201.0M 12.0% | -$239.0M -13.4% | $225.0M 13.0% | $244.0M 13.0% |
Large figure: segment operating income. Below it the margin, that is operating income measured against the revenue of the same segment.
Revenue by region
| Segment | Q1 2025 | Q2 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
| North America | $2.58B 45.0% | $2.44B 41.1% | $2.48B 41.6% | $2.47B 39.5% |
| High-growth markets | $1.54B 26.8% | $1.70B 28.6% | $1.62B 27.3% | $1.96B 31.3% |
| Western Europe | $1.34B 23.4% | $1.51B 25.4% | $1.57B 26.3% | $1.54B 24.6% |
| Other developed markets | $278.0M 4.8% | $294.0M 5.0% | $284.0M 4.8% | $293.0M 4.7% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Revenue by product line
| Segment | Q1 2025 | Q2 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
| Recurring revenue | $4.82B 83.9% | $4.97B 83.7% | $5.03B 84.5% | $5.20B 83.0% |
| Nonrecurring revenue | $925.0M 16.1% | $966.0M 16.3% | $920.0M 15.5% | $1.07B 17.0% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Remaining performance obligations
Remaining performance obligations are the part of the business already sold but not yet delivered and therefore not yet booked as revenue. In subscription and project businesses it points the way earlier than revenue does.
| As of | Remaining performance obligations |
|---|---|
| Q2 2026 | $7.50B |
| Q1 2026 | $5.30B |
| Q4 2025 | $5.20B |
| Q3 2025 | $4.90B |
| Q2 2025 | $4.90B |
| Q1 2025 | $4.50B |
| Q4 2024 | $4.30B |
| Q3 2024 | $4.40B |
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.